Quest Diagnostics Files Definitive Proxy Materials

TL;DR

Quest Diagnostics just dropped their proxy statement - time to vote!

AI Summary

Quest Diagnostics Incorporated filed a Definitive Additional Materials proxy statement on April 11, 2025. This filing is related to their annual meeting and likely contains information about executive compensation, director nominations, and other shareholder proposals. The company, previously known as Corning Clinical Laboratories Inc., is incorporated in Delaware and headquartered in Secaucus, NJ.

Why It Matters

This filing provides shareholders with crucial information needed to make informed decisions regarding company governance, executive pay, and voting on important matters at the upcoming annual meeting.

Risk Assessment

Risk Level: low — This is a routine proxy filing, not indicating any immediate financial distress or significant new risks.

Key Players & Entities

• Quest Diagnostics Incorporated (company) — Registrant
• Corning Clinical Laboratories Inc. (company) — Former company name
• Secaucus, NJ (location) — Company headquarters
• April 11, 2025 (date) — Filing date

FAQ

From the Filing

0000947871-25-000382.txt : 20250411 0000947871-25-000382.hdr.sgml : 20250411 20250411162546 ACCESSION NUMBER: 0000947871-25-000382 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20250411 DATE AS OF CHANGE: 20250411 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 25832406 BUSINESS ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 DEFA14A 1 ss4699717_defa14a.htm PROXY STATEMENT PURSUANT TO SECTION 14(A) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ 	Preliminary Proxy Statement ☐ 	CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (as permitted by Rule 14a-6(e)(2)) ☐ 	Definitive Proxy Statement ☒ 	Definitive Additional Materials ☐ 	Soliciting Material Pursuant to Section 240.14a-12 Quest Diagnostics Incorporated (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ 	No fee required. ☐ 	Fee paid previously with preliminary materials. ☐ 	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 Quest Diagnostics Incorporated SUPPLEMENT TO PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 15, 2025 Explanatory Note On April 4, 2025, Quest Diagnostics Incorporated (the “Company”) filed its Definitive Proxy Statement on Schedule 14A (the “Proxy Statement”) with the Securities and Exchange Commission and furnished it to stockholders in connection with the solicitation of proxies by the Board of Directors for use at the 2025 Annual Meeting of Stockholders of the Company to be held on May 15, 2025 (the “Annual Meeting”). The purpose of this supplement, dated April 11, 2025 (this “Supplement”), is solely to correct a typographical error on page 69 of the Proxy Statement as set forth below under the heading “Change to the Proxy Statement.” Other than this change, the Proxy Statement remains unchanged, and this Supplement does not otherwise modify, amend, supplement or affect the Proxy Statement. From and after the date of this Supplement, any references to the “Proxy Statement” are to the Proxy Statement as amended and supplemented by this Supplement. This Supplement should be read in conjunction with the Proxy Statement and the other proxy materials previously distributed for the Annual Meeting. Change to the Proxy Statement The following disclosure (change marked, with new text bold and underlined and deleted text bold and strikethrough) amends and supplements the information provided in the section entitled “Frequently Asked Questions” beginning on page 69 of the Proxy Statement: 2. How many votes can be cast by all stockholders? On the record date, there were 11,612,391 111,612,391 shares of our common stock outstanding, each of which is entitled to one vote for each matter to be voted on at the Annual Meeting.